ledipasvir + GS-9451 + tegobuvir

This drug is a fixed combination of three direct-acting antivirals: **ledipasvir** (GS-5885), an NS5A inhibitor; **GS-9451**, an NS3/4A protease inhibitor; and **tegobuvir** (GS-9190), a non-nucleoside inhibitor targeting the NS5B polymerase thumb site II of hepatitis C virus (HCV). The combination was developed to provide a potent, all-oral, interferon-free regimen for chronic hepatitis C genotype 1 infection. The triple regimen was evaluated in phase 2 clinical studies (often with or without ribavirin) to improve virologic response rates and to enable shorter durations of therapy for HCV, especially in treatment-experienced or difficult-to-treat patients.

Other names

ledipasvir + vedroprevir + tegobuvir